This is a table of type unigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
unigram | frequency |
---|---|
patients | 22994 |
cell | 8061 |
cells | 6653 |
hsct | 6041 |
cd | 5954 |
disease | 5503 |
treatment | 4717 |
transplantation | 4661 |
patient | 4471 |
median | 4345 |
gvhd | 4145 |
transplant | 4070 |
years | 3936 |
stem | 3855 |
results | 3425 |
days | 3261 |
months | 3248 |
risk | 3231 |
donor | 3222 |
therapy | 3175 |
study | 3148 |
group | 3051 |
age | 3010 |
day | 2970 |
clinical | 2949 |
received | 2944 |
high | 2846 |
one | 2821 |
pts | 2729 |
blood | 2719 |
acute | 2638 |
associated | 2551 |
infection | 2497 |
time | 2488 |
survival | 2486 |
mg | 2475 |
allogeneic | 2465 |
infections | 2423 |
range | 2354 |
vs | 2342 |
conditioning | 2314 |
relapse | 2252 |
two | 2245 |
kg | 2178 |
post | 2163 |
may | 2161 |
analysis | 2143 |
diagnosis | 2119 |
year | 2077 |
severe | 2032 |
graft | 2001 |
cases | 1915 |
respectively | 1896 |
dose | 1888 |
using | 1867 |
related | 1858 |
data | 1856 |
hematopoietic | 1856 |
significant | 1801 |
marrow | 1794 |
used | 1782 |
response | 1751 |
chronic | 1750 |
performed | 1747 |
incidence | 1745 |
immune | 1740 |
first | 1738 |
cmv | 1728 |
recipients | 1725 |
compared | 1717 |
non | 1706 |
methods | 1698 |
children | 1670 |
also | 1650 |
sct | 1625 |
mortality | 1619 |
allo | 1612 |
bone | 1606 |
due | 1603 |
os | 1564 |
however | 1556 |
treated | 1550 |
follow | 1535 |
background | 1534 |
low | 1524 |
showed | 1514 |
without | 1498 |
developed | 1486 |
overall | 1477 |
higher | 1470 |
based | 1470 |
case | 1464 |
levels | 1456 |
regimen | 1450 |
prophylaxis | 1450 |
donors | 1429 |
reported | 1417 |
well | 1410 |
grade | 1392 |
use | 1387 |
primary | 1374 |
ci | 1371 |
including | 1370 |
respiratory | 1370 |
early | 1369 |
increased | 1348 |
cr | 1347 |
hla | 1335 |
significantly | 1328 |
syndrome | 1325 |
leukemia | 1311 |
aml | 1278 |
hct | 1271 |
following | 1267 |
conclusions | 1252 |
number | 1244 |
normal | 1243 |
total | 1241 |
versus | 1240 |
included | 1236 |
engraftment | 1235 |
chemotherapy | 1234 |
observed | 1234 |
pediatric | 1232 |
autologous | 1200 |
positive | 1196 |
rate | 1179 |
unrelated | 1176 |
studies | 1173 |
failure | 1170 |
complications | 1164 |
peripheral | 1153 |
disclosure | 1143 |
outcome | 1140 |
i | 1133 |
agvhd | 1126 |
three | 1120 |
factors | 1116 |
groups | 1114 |
anti | 1113 |
matched | 1092 |
specific | 1086 |
deficiency | 1061 |
reduced | 1056 |
virus | 1055 |
found | 1051 |
hospital | 1049 |
lower | 1023 |
outcomes | 1004 |
diagnosed | 1003 |
viral | 1001 |
host | 988 |
cohort | 977 |
identified | 976 |
lymphoma | 973 |
underwent | 972 |
nk | 962 |
prior | 955 |
gene | 947 |
ml | 945 |
il | 945 |
complete | 941 |
function | 938 |
negative | 932 |
pre | 927 |
report | 917 |
symptoms | 912 |
lung | 911 |
second | 910 |
different | 906 |
old | 902 |
died | 894 |
atg | 892 |
among | 891 |
asct | 890 |
expression | 873 |
haploidentical | 864 |
common | 859 |
none | 856 |
remission | 847 |
present | 846 |
mutations | 841 |
refractory | 841 |
control | 841 |
cancer | 837 |
center | 836 |
within | 831 |
immunodeficiency | 829 |
period | 828 |
free | 825 |
mutation | 825 |
multiple | 819 |
diseases | 814 |
pulmonary | 809 |
mean | 806 |
population | 798 |
given | 794 |
long | 792 |
development | 790 |
iv | 789 |
single | 782 |
cgvhd | 780 |
term | 779 |
analyzed | 776 |
effect | 774 |
care | 773 |
transplanted | 771 |
presented | 766 |
pneumonia | 763 |
retrospective | 759 |
conclusion | 753 |
followed | 751 |
status | 750 |
type | 750 |
human | 750 |
ii | 748 |
count | 746 |
interest | 746 |
male | 745 |
igg | 743 |
level | 739 |
cause | 736 |
liver | 733 |
toxicity | 732 |
chimerism | 730 |
according | 728 |
impact | 725 |
factor | 724 |
although | 723 |
revealed | 722 |
oral | 719 |
role | 715 |
recurrent | 713 |
infectious | 702 |
cyclophosphamide | 701 |
skin | 700 |
receiving | 697 |
ric | 693 |
genetic | 693 |
medical | 693 |
increase | 688 |
rates | 687 |
method | 686 |
platelet | 686 |
recovery | 685 |
mm | 685 |
weeks | 684 |
evaluated | 678 |
adult | 677 |
myeloablative | 673 |
ebv | 668 |
considered | 668 |
relapsed | 667 |
malignancies | 666 |
progression | 661 |
effects | 660 |
reactivation | 658 |
occurred | 657 |
lymphocyte | 657 |
will | 657 |
four | 655 |
history | 653 |
potential | 649 |
effective | 643 |
csf | 642 |
standard | 640 |
cord | 640 |
secondary | 637 |
regimens | 637 |
haplo | 631 |
poor | 630 |
hr | 630 |
female | 630 |
similar | 629 |
important | 628 |
achieved | 619 |
pcr | 615 |
samples | 615 |
new | 610 |
despite | 610 |
life | 609 |
decreased | 608 |
death | 606 |
tumor | 606 |
evaluation | 605 |
infusion | 604 |
improved | 600 |
objectives | 599 |
major | 595 |
criteria | 594 |
shown | 592 |
test | 592 |
efficacy | 586 |
university | 585 |
addition | 584 |
activity | 583 |
intensity | 581 |
system | 580 |
fever | 579 |
phase | 576 |
serum | 574 |
bm | 568 |
less | 567 |
dl | 567 |
introduction | 563 |
management | 560 |
onset | 558 |
neutrophil | 558 |
previously | 557 |
difference | 553 |
detected | 552 |
table | 552 |
presence | 551 |
demonstrated | 549 |
findings | 549 |
prospective | 549 |
per | 547 |
mrd | 547 |
sibling | 546 |
limited | 546 |
available | 543 |
five | 543 |
myeloid | 541 |
healthy | 540 |
conflict | 540 |
induction | 538 |
protein | 538 |
antibody | 537 |
neutropenia | 537 |
recipient | 537 |
cy | 536 |
defined | 535 |
experience | 532 |
source | 529 |
scid | 529 |
better | 528 |
differences | 527 |
trial | 524 |
family | 521 |
since | 519 |
therapeutic | 517 |
required | 513 |
transplants | 513 |
vod | 513 |
busulfan | 510 |
collected | 508 |
testing | 508 |
additional | 507 |
flow | 506 |
novel | 504 |
cumulative | 502 |
combination | 500 |
iii | 498 |
influenza | 498 |
rare | 497 |
described | 496 |
dna | 496 |
disorders | 493 |
pain | 491 |
either | 491 |
undergoing | 491 |
dli | 490 |
late | 489 |
fludarabine | 488 |
improvement | 485 |
previous | 485 |
nrm | 484 |
sequencing | 483 |
lymphocytes | 483 |
administration | 482 |
line | 480 |
known | 479 |
several | 479 |
autoimmune | 478 |
characteristics | 477 |
score | 476 |
ct | 475 |
setting | 475 |
inflammatory | 474 |
pt | 471 |
evidence | 471 |
anemia | 470 |
remains | 468 |
combined | 468 |
initial | 467 |
started | 467 |
month | 466 |
mds | 466 |
seen | 465 |
events | 463 |
evaluate | 462 |
episodes | 461 |
course | 461 |
tbi | 461 |
biopsy | 460 |
obtained | 458 |
health | 456 |
still | 455 |
doses | 455 |
least | 455 |
pid | 451 |
safety | 451 |
elevated | 448 |
adverse | 446 |
organ | 445 |
research | 444 |
six | 443 |
reconstitution | 439 |
complication | 435 |
review | 435 |
myeloma | 434 |
mobilization | 434 |
protocol | 434 |
weight | 434 |
confirmed | 433 |
need | 433 |
laboratory | 432 |
responses | 431 |
ecp | 430 |
loss | 425 |
approach | 424 |
features | 423 |
drug | 422 |
fungal | 422 |
rsv | 416 |
presentation | 415 |
trm | 415 |
frequent | 414 |
assessed | 414 |
possible | 414 |
renal | 414 |
often | 414 |
pfs | 410 |
pbsc | 409 |
procedure | 408 |
alive | 408 |
hematological | 407 |
recent | 406 |
aim | 406 |
characterized | 406 |
even | 405 |
improve | 405 |
phenotype | 404 |
molecular | 403 |
last | 402 |
scd | 402 |
systemic | 402 |
antigen | 399 |
counts | 399 |
auto | 398 |
many | 398 |
immunoglobulin | 398 |
administered | 397 |
transfusion | 396 |
include | 395 |
invasive | 395 |
later | 394 |
adults | 394 |
stage | 394 |
frequency | 393 |
genes | 392 |
identical | 392 |
tract | 392 |
ratio | 392 |
cvid | 391 |
duration | 391 |
support | 390 |
reduction | 390 |
steroid | 389 |
series | 389 |
association | 388 |
diagnostic | 388 |
large | 388 |
identify | 387 |
majority | 387 |
melphalan | 386 |
suggest | 386 |
needed | 386 |
induced | 385 |
multivariate | 385 |
determine | 384 |
bacterial | 384 |
morbidity | 383 |
active | 381 |
receptor | 381 |
car | 380 |
vivo | 380 |
therefore | 379 |
mud | 378 |
especially | 377 |
model | 377 |
controls | 376 |
quality | 373 |
activation | 373 |
design | 373 |
malignancy | 372 |
mice | 372 |
retrospectively | 372 |
progressive | 372 |
proliferation | 370 |
cytometry | 370 |
baseline | 369 |
hematologic | 369 |
small | 369 |
body | 368 |
rituximab | 367 |
malignant | 367 |
option | 365 |
agents | 364 |
whereas | 364 |
plasma | 364 |
variant | 363 |
consisted | 363 |
centers | 363 |
good | 361 |
memory | 360 |
antibodies | 359 |
result | 359 |
declare | 359 |
decrease | 357 |
vaccine | 357 |
screening | 356 |
whole | 355 |
culture | 354 |
likely | 354 |
bmt | 354 |
grafts | 352 |
igm | 351 |
viruses | 351 |
collection | 348 |
nothing | 347 |
target | 347 |
consecutive | 344 |
currently | 344 |
ivig | 343 |
whether | 343 |
ebmt | 342 |
monitoring | 342 |
therapies | 342 |
depletion | 342 |
changes | 341 |
cgd | 341 |
experienced | 339 |
tissue | 339 |
partial | 339 |
might | 338 |
mismatched | 337 |
bleeding | 337 |
prognosis | 336 |
involvement | 335 |
tcr | 335 |
order | 334 |
detection | 332 |
mild | 332 |
affected | 330 |
lesions | 328 |
average | 326 |
assess | 326 |
immunosuppression | 326 |
assay | 326 |
current | 325 |
immunosuppressive | 324 |
vitro | 324 |
describe | 323 |
like | 322 |
strategy | 322 |
causes | 320 |
caused | 320 |
th | 320 |
show | 318 |
unit | 318 |
daily | 316 |
value | 315 |
cyclosporine | 314 |
nhl | 313 |
ifn | 312 |
infused | 312 |
absence | 312 |
stat | 311 |
adenovirus | 310 |
steroids | 310 |
reports | 309 |
persistent | 309 |
allosct | 309 |
alternative | 308 |
csa | 308 |
successful | 306 |
regarding | 306 |
advanced | 304 |
statistically | 303 |
values | 302 |
measured | 302 |
eight | 302 |
sepsis | 302 |
studied | 302 |
severity | 301 |
full | 301 |
numbers | 301 |
disorder | 300 |
underlying | 299 |
subjects | 299 |
pr | 299 |
immunocompromised | 299 |
process | 299 |
signs | 299 |
develop | 298 |
assessment | 298 |
variants | 297 |
moderate | 297 |
co | 297 |
seven | 296 |
bu | 294 |
thrombocytopenia | 294 |
curative | 294 |
main | 293 |
tumors | 293 |
solid | 293 |
vaccination | 293 |
lines | 291 |
intravenous | 291 |
established | 291 |
week | 291 |
reduce | 289 |
resulting | 288 |
variable | 288 |
january | 288 |
heterozygous | 287 |
derived | 287 |
st | 287 |
oncology | 286 |
recently | 286 |
mixed | 286 |
older | 286 |
hlh | 285 |
alone | 285 |
provide | 285 |
extensive | 283 |
strategies | 283 |
functional | 282 |
tested | 282 |
short | 281 |
leading | 281 |
ra | 280 |
frequently | 280 |
dysfunction | 280 |
cytokine | 280 |
depleted | 280 |
requiring | 280 |
lack | 280 |
inflammation | 280 |
abnormalities | 280 |
resulted | 279 |
safe | 279 |
trials | 279 |
hematology | 278 |
central | 278 |
information | 278 |
survivors | 278 |
guidelines | 278 |
immunity | 277 |
parents | 277 |
part | 276 |
prognostic | 275 |
index | 275 |
conducted | 274 |
national | 274 |
increasing | 274 |
prevent | 274 |
ptcy | 274 |
hhv | 273 |
prevention | 273 |
lead | 273 |
salvage | 273 |
resistant | 273 |
particularly | 272 |
cellular | 272 |
stable | 271 |
institution | 270 |
receive | 270 |
manifestations | 270 |
randomized | 269 |
conditions | 269 |
tests | 268 |
rejection | 268 |
production | 268 |
twenty | 266 |
admission | 266 |
end | 265 |
pb | 265 |
mediated | 265 |
side | 265 |
remained | 264 |
event | 263 |
plus | 262 |
consistent | 262 |
prolonged | 261 |
enrolled | 261 |
states | 260 |
comparison | 260 |
subsequent | 260 |
antiviral | 260 |
hl | 259 |
literature | 259 |
isolated | 259 |
continued | 257 |
involved | 256 |
absolute | 256 |
independent | 256 |
selected | 256 |
individuals | 255 |
registry | 255 |
conventional | 255 |
benefit | 255 |
abnormal | 254 |
procedures | 254 |
clinically | 252 |
rapid | 252 |
platelets | 251 |
noted | 251 |
selection | 251 |
program | 251 |
highly | 250 |
inhibitor | 250 |
every | 250 |
subsets | 250 |
targeted | 250 |
date | 250 |
linked | 249 |
wt | 249 |
parameters | 249 |
infants | 249 |
documented | 248 |
expansion | 247 |
determined | 247 |
analyses | 247 |
product | 247 |
mucositis | 246 |
gastrointestinal | 246 |
cytomegalovirus | 246 |
methotrexate | 245 |
resolution | 245 |
lymphopenia | 245 |
united | 244 |
correlation | 244 |
irradiation | 243 |
cycles | 242 |
nine | 242 |
young | 242 |
third | 242 |
flu | 241 |
growth | 241 |
replacement | 241 |
developing | 240 |
beam | 239 |
lymphoblastic | 238 |
various | 238 |
infusions | 237 |
antibiotics | 237 |
physical | 237 |
drugs | 237 |
successfully | 237 |
times | 237 |
complex | 237 |
dfs | 237 |
longer | 236 |
published | 236 |
cultures | 236 |
nd | 235 |
pathway | 235 |
aged | 235 |
tacrolimus | 234 |
prevalence | 234 |
potentially | 234 |
efs | 234 |
dependent | 234 |
statistical | 233 |
another | 233 |
males | 232 |
defects | 232 |
sample | 232 |
apheresis | 231 |
iga | 231 |
females | 231 |
weekly | 230 |
serious | 230 |
sirolimus | 230 |
volume | 229 |
significance | 229 |
models | 229 |
general | 229 |
optimal | 229 |
intensive | 228 |
ng | 228 |
chest | 228 |
gi | 228 |
haematopoietic | 228 |
left | 227 |
sos | 227 |
comparable | 226 |
products | 226 |
tolerated | 226 |
prophylactic | 226 |
commonly | 225 |
transfusions | 225 |
ul | 225 |
made | 225 |
feasible | 224 |
immunological | 224 |
msd | 224 |
centre | 224 |
investigated | 223 |
stimulation | 222 |
posttransplant | 222 |
percentage | 222 |
generation | 222 |
department | 222 |
unknown | 222 |
upper | 221 |
diffuse | 221 |
ongoing | 221 |
hypogammaglobulinemia | 221 |
mscs | 221 |
injury | 220 |
correlated | 220 |
mainly | 219 |
best | 219 |
reviewed | 218 |
remaining | 218 |
initiated | 217 |
markers | 217 |
thalassemia | 216 |
regression | 216 |
ribavirin | 216 |
activated | 216 |
inhibitors | 216 |
allohsct | 216 |
imaging | 216 |
neutropenic | 215 |
practice | 215 |
mac | 215 |
kidney | 215 |
residual | 215 |
plerixafor | 214 |
treatments | 214 |
pet | 213 |
except | 213 |
condition | 213 |
hours | 212 |
work | 212 |
ms | 211 |
hepatic | 211 |
future | 211 |
usually | 211 |
ruxolitinib | 211 |
us | 211 |
globulin | 210 |
proportion | 210 |
fi | 209 |
delayed | 209 |
treat | 209 |
acid | 209 |
sex | 208 |
corticosteroids | 208 |
variables | 208 |
recommended | 208 |
msc | 208 |
via | 208 |
done | 208 |
objective | 207 |
diarrhea | 207 |
impaired | 207 |
childhood | 207 |
abdominal | 207 |
appropriate | 207 |
terms | 207 |
mri | 206 |
febrile | 206 |
greater | 206 |
probability | 206 |
maintenance | 206 |
estimated | 206 |
compare | 205 |
thiotepa | 205 |
brain | 204 |
ctla | 204 |
child | 204 |
abstract | 204 |
hodgkin | 204 |
agent | 203 |
mtx | 203 |
intermediate | 203 |
survey | 203 |
expressed | 202 |
clinic | 202 |
intervention | 202 |
beta | 202 |
populations | 202 |
completed | 202 |
starting | 201 |
neutrophils | 201 |
radiation | 201 |
hepatitis | 201 |
signaling | 200 |
interval | 200 |
univariate | 200 |
disseminated | 200 |
pathogenic | 199 |
lfs | 199 |
form | 198 |
subsequently | 198 |
hospitalization | 198 |
tma | 198 |
assays | 198 |
gender | 198 |
bacteremia | 197 |
institute | 197 |
cardiac | 197 |
site | 196 |
controlled | 195 |
december | 195 |
initiation | 195 |
applied | 195 |
able | 194 |
antifungal | 194 |
minimal | 194 |
panel | 194 |
immunology | 194 |
now | 193 |
occur | 193 |
engrafted | 193 |
suspected | 193 |
examination | 192 |
reached | 191 |
mmf | 191 |
arm | 190 |
spectrum | 190 |
exposure | 190 |
key | 190 |
occurrence | 190 |
others | 190 |
hemoglobin | 190 |
cml | 189 |
multi | 189 |
antibiotic | 189 |
po | 189 |
influence | 188 |
remain | 188 |
icu | 187 |
treosulfan | 187 |
concentration | 187 |
failed | 186 |
treg | 186 |
mycophenolate | 186 |
presenting | 186 |
copies | 185 |
cost | 185 |
ig | 185 |
deaths | 185 |
analysed | 184 |
dock | 184 |
rhinovirus | 184 |
start | 183 |
damage | 183 |
led | 183 |
finally | 183 |
point | 182 |
promising | 182 |
profile | 182 |
load | 182 |
autoimmunity | 182 |
yrs | 182 |
hiv | 182 |
identification | 181 |
suggesting | 181 |
cytotoxic | 181 |
consolidation | 181 |
scores | 181 |
bronchiolitis | 181 |
complement | 181 |
authors | 181 |
exome | 180 |
referred | 180 |
demonstrate | 180 |
lymphoid | 180 |
excluded | 180 |
contrast | 180 |
next | 180 |
approximately | 180 |
threatening | 179 |
necessary | 179 |
cytokines | 179 |
change | 179 |
lymphoproliferative | 178 |
furthermore | 178 |
hc | 178 |
class | 178 |
containing | 178 |
knowledge | 178 |
local | 176 |
anc | 176 |
state | 176 |
right | 176 |
double | 176 |
yet | 175 |
red | 175 |
endothelial | 175 |
relevant | 175 |
carv | 174 |
etoposide | 174 |
mononuclear | 174 |
suggests | 174 |
protective | 174 |
larger | 174 |
initially | 173 |
alemtuzumab | 173 |
ige | 173 |
bos | 172 |
leukaemia | 172 |
autosomal | 172 |
proven | 172 |
additionally | 171 |
blasts | 171 |
cns | 171 |
moreover | 171 |
sickle | 171 |
regulatory | 170 |
critical | 170 |
homozygous | 170 |
achieve | 169 |
records | 169 |
international | 169 |
intestinal | 168 |
medicine | 168 |
particular | 168 |
fibrosis | 168 |
supportive | 168 |
cycle | 168 |
approved | 168 |
cystitis | 168 |
ex | 167 |
ifd | 167 |
capacity | 167 |
admitted | 167 |
pathogens | 167 |
confirm | 166 |
effector | 166 |
defect | 166 |
differentiation | 166 |
acquired | 166 |
calculated | 166 |
responded | 166 |
syncytial | 165 |
points | 165 |
expanded | 165 |
aplastic | 165 |
delay | 165 |
resistance | 165 |
rag | 165 |
diagnoses | 165 |
options | 165 |
dc | 164 |
hsc | 164 |
susceptibility | 164 |
signifi | 164 |
help | 164 |
relatively | 163 |
european | 163 |
units | 163 |
eligible | 163 |
indicated | 163 |
gain | 163 |
pi | 163 |
fatal | 163 |
fluid | 162 |
investigate | 162 |
aimed | 162 |
cohorts | 162 |
tcd | 161 |
vascular | 161 |
immunotherapy | 161 |
predictive | 161 |
quantitative | 160 |
gamma | 160 |
ahsct | 160 |
mass | 160 |
resolved | 160 |
monoclonal | 160 |
real | 160 |
ten | 159 |
difficult | 159 |
scan | 159 |
toxicities | 159 |
recurrence | 158 |
provided | 158 |
reaction | 158 |
episode | 158 |
hd | 158 |
mechanism | 157 |
comparing | 157 |
wbc | 157 |
bk | 157 |
heart | 157 |
aspergillus | 157 |
dysregulation | 156 |
database | 155 |
antigens | 155 |
gy | 155 |
sustained | 155 |
typically | 155 |
adv | 155 |
relative | 155 |
tool | 155 |
es | 155 |
organs | 155 |
deletion | 155 |
alpha | 154 |
expected | 154 |
classified | 154 |
shows | 154 |
routine | 153 |
performance | 153 |
importance | 153 |
pd | 153 |
lymph | 152 |
aspergillosis | 152 |
mofetil | 152 |
iron | 152 |
absent | 152 |
cutaneous | 152 |
rna | 151 |
chain | 151 |
ada | 151 |
tki | 151 |
types | 150 |
cm | 150 |
younger | 150 |
subset | 150 |
trend | 150 |
protocols | 150 |
gut | 150 |
thymic | 150 |
individual | 149 |
syndromes | 149 |
siblings | 149 |
participants | 149 |
complicated | 149 |
bacteria | 149 |
viremia | 148 |
earlier | 148 |
affect | 148 |
immunodeficiencies | 148 |
nih | 148 |
families | 148 |
suggested | 148 |
application | 148 |
idiopathic | 148 |
cb | 147 |
candida | 147 |
titers | 147 |
cll | 147 |
self | 147 |
countries | 147 |
useful | 147 |
biopsies | 147 |
tregs | 147 |
occurs | 146 |
id | 146 |
pattern | 146 |
ability | 146 |
added | 146 |
responders | 145 |
deficient | 145 |
hypertension | 145 |
mechanisms | 145 |
hemorrhage | 145 |
generally | 145 |
size | 145 |
text | 145 |
surgical | 144 |
obliterans | 144 |
mobilized | 144 |
investigation | 144 |
require | 144 |
half | 144 |
bal | 144 |
defibrotide | 143 |
monitored | 143 |
discontinued | 143 |
direct | 143 |
cytogenetic | 143 |
flt | 143 |
deficiencies | 143 |
fully | 142 |
allohct | 142 |
dosing | 142 |
aggressive | 142 |
adequate | 142 |
sensitivity | 142 |
sd | 141 |
favorable | 141 |
june | 141 |
preliminary | 141 |
natural | 141 |
binding | 140 |
distribution | 140 |
placebo | 140 |
continuous | 140 |
inhibition | 140 |
towards | 140 |
observation | 140 |
metastatic | 140 |
mel | 140 |
immunologic | 140 |
fl | 139 |
fold | 139 |
indicate | 139 |
ips | 139 |
seems | 139 |
min | 139 |
viability | 139 |
recorded | 139 |
essential | 139 |
trec | 139 |
ph | 139 |
marker | 138 |
analyze | 138 |
region | 138 |
along | 138 |
chart | 138 |
gram | 137 |
occlusive | 137 |
myelodysplastic | 137 |
approaches | 137 |
neuroblastoma | 137 |
symptomatic | 137 |
thirty | 136 |
hemorrhagic | 136 |
alveolar | 136 |
aa | 136 |
congenital | 136 |
corticosteroid | 136 |
hmpv | 136 |
multicenter | 136 |
length | 136 |
ptld | 136 |
generated | 136 |
card | 136 |
newly | 135 |
risks | 135 |
relationship | 135 |
allergy | 135 |
granulomatous | 135 |
twice | 134 |
predicted | 134 |
decision | 134 |
mismatch | 134 |
surface | 134 |
apoptosis | 134 |
play | 134 |
rash | 133 |
leukemic | 133 |
though | 133 |
ucb | 133 |
involving | 133 |
unique | 133 |
degree | 133 |
broad | 133 |
infected | 133 |
jak | 132 |
sites | 132 |
allogenic | 132 |
atypical | 132 |
pathogen | 132 |
november | 132 |
percent | 132 |
conditioned | 132 |
haematological | 131 |
clear | 131 |
community | 131 |
adherence | 131 |
ferritin | 131 |
measures | 131 |
home | 131 |
indication | 130 |
genotype | 130 |
umbilical | 130 |
basis | 130 |
already | 130 |
allograft | 130 |
pg | 129 |
causing | 129 |
materials | 129 |
bortezomib | 129 |
nf | 129 |
targeting | 129 |
team | 129 |
imatinib | 129 |
interferon | 129 |
cytopenias | 129 |
parainfluenza | 128 |
om | 128 |
foxp | 128 |
almost | 128 |
concentrations | 128 |
contribute | 128 |
far | 127 |
set | 127 |
mcl | 127 |
education | 127 |
affecting | 127 |
cxcr | 127 |
rr | 127 |
cidofovir | 126 |
kinase | 126 |
tnf | 126 |
surveillance | 126 |
detect | 125 |
newborn | 125 |
repertoire | 125 |
hies | 125 |
declared | 125 |
surgery | 125 |
consensus | 125 |
become | 124 |
recognized | 124 |
indications | 124 |
excellent | 124 |
allele | 124 |
kir | 124 |
proteins | 124 |
lymphomas | 124 |
burden | 124 |
urine | 124 |
adoptive | 124 |
together | 124 |
must | 124 |
splenomegaly | 124 |
birth | 124 |
cryopreserved | 124 |
log | 123 |
leads | 123 |
pathogenesis | 123 |
hdct | 123 |
rd | 123 |
recommendations | 123 |
highest | 123 |
predict | 123 |
chromosome | 123 |
lrti | 122 |
mother | 122 |
tandem | 122 |
recessive | 122 |
reactions | 121 |
centres | 121 |
medications | 121 |
worse | 121 |
suffered | 121 |
elderly | 121 |
showing | 121 |
monocytes | 121 |
interestingly | 120 |
staff | 120 |
july | 120 |
modified | 120 |
provides | 120 |
neurological | 120 |
october | 120 |
symptom | 120 |
illness | 120 |
qol | 119 |
occurring | 119 |
sot | 119 |
project | 119 |
institutional | 119 |
ranging | 119 |
past | 119 |
transfer | 119 |
maximum | 118 |
vaccines | 118 |
outpatient | 118 |
veno | 118 |
dlbcl | 118 |
examined | 118 |
mucosal | 118 |
medication | 118 |
understanding | 118 |
granulocyte | 118 |
lymphadenopathy | 118 |
scale | 118 |
hb | 118 |
origin | 117 |
interstitial | 117 |
inclusion | 117 |
metabolic | 117 |
venous | 117 |
adjusted | 117 |
cytarabine | 117 |
mnc | 117 |
isolation | 117 |
asymptomatic | 117 |
antimicrobial | 117 |
around | 117 |
paediatric | 117 |
carried | 117 |
respond | 117 |
species | 116 |
unclear | 116 |
working | 116 |
del | 116 |
radiotherapy | 116 |
met | 116 |
bkv | 116 |
forms | 116 |
courses | 116 |
needs | 116 |
society | 116 |
appears | 116 |
reference | 116 |
mostly | 116 |
release | 116 |
rv | 115 |
circulating | 115 |
cox | 115 |
represents | 115 |
predominantly | 115 |
discharge | 115 |
consent | 115 |
ta | 115 |
represent | 115 |
stimulated | 115 |
area | 114 |
yield | 114 |
leukocyte | 114 |
material | 114 |
allows | 114 |
infant | 114 |
tissues | 114 |
saa | 114 |
gt | 114 |
expressing | 114 |
die | 114 |
training | 113 |
little | 113 |
divided | 113 |
problems | 113 |
repeated | 113 |
reactive | 113 |
phox | 113 |
tolerance | 113 |
dominant | 113 |
ucbt | 113 |
taken | 113 |
auc | 113 |
mir | 112 |
includes | 112 |
cbt | 112 |
peak | 112 |
undergone | 112 |
cytotoxicity | 112 |
interventions | 112 |
prednisone | 112 |
bilateral | 112 |
evaluable | 112 |
cytogenetics | 111 |
novo | 111 |
pneumococcal | 111 |
physicians | 111 |
ccr | 111 |
progenitor | 111 |
bowel | 111 |
white | 110 |
school | 110 |
choice | 110 |
ifi | 110 |
discussion | 110 |
gvl | 110 |
across | 110 |
wide | 110 |
prospectively | 110 |
voriconazole | 110 |
specifi | 110 |
providers | 110 |
allow | 110 |
rapidly | 110 |
widely | 109 |
sr | 109 |
nausea | 109 |
sensitive | 109 |
killer | 109 |
etiology | 109 |
hbv | 109 |
hydroxyurea | 109 |
became | 108 |
staining | 108 |
kaplan | 108 |
dexamethasone | 108 |
improving | 108 |
pneumonitis | 108 |
making | 108 |
formation | 108 |
oxygen | 108 |
sarcoma | 108 |
iqr | 107 |
receptors | 107 |
neither | 107 |
subcutaneous | 107 |
girl | 107 |
rfs | 107 |
effectiveness | 107 |
bcg | 107 |
noninfectious | 106 |
bmi | 106 |
impairment | 106 |
match | 106 |
distinct | 106 |
crs | 106 |
pathology | 106 |
lymphocytic | 106 |
timing | 106 |
ed | 106 |
ventilation | 106 |
strongly | 106 |
classification | 106 |
inherited | 106 |
suppression | 105 |
feasibility | 105 |
supported | 105 |
ri | 105 |
purpose | 105 |
finding | 105 |
induce | 105 |
ganciclovir | 105 |
reducing | 105 |
phenotypes | 105 |
dmso | 105 |
informed | 105 |
adolescents | 105 |
cure | 105 |
party | 105 |
switched | 105 |
validated | 104 |
pregnancy | 104 |
beneficial | 104 |
pids | 104 |
rst | 104 |
grfs | 104 |
search | 104 |
increases | 104 |
nkg | 104 |
preemptive | 103 |
colitis | 103 |
superior | 103 |
alps | 103 |
piv | 103 |
concern | 103 |
endpoint | 103 |
context | 103 |
depending | 103 |
specifically | 102 |
consisting | 102 |
differ | 102 |
similarly | 102 |
ranged | 102 |
repeat | 102 |
american | 102 |
ad | 102 |
sources | 101 |
transcription | 101 |
strong | 101 |
myelofibrosis | 101 |
cough | 101 |
understand | 101 |
final | 101 |
discontinuation | 101 |
progress | 101 |
immunoglobulins | 100 |
mo | 100 |
marked | 100 |
ab | 100 |
transplantations | 100 |
rbc | 100 |
boy | 100 |
undergo | 100 |
peptide | 100 |
ibd | 100 |
directed | 100 |
detectable | 100 |
women | 99 |
distress | 99 |
open | 99 |
hsv | 99 |
ctls | 99 |
lesion | 99 |
ds | 99 |
pretransplant | 99 |
transient | 99 |
fusion | 99 |
members | 99 |
mouse | 99 |
manifestation | 99 |
herpes | 98 |
rather | 98 |
rank | 98 |
calcineurin | 98 |
access | 98 |
unmanipulated | 98 |
hospitalized | 98 |
meier | 98 |
hyper | 98 |
availability | 98 |
considering | 98 |
directly | 98 |
clearance | 98 |
cryopreservation | 98 |
comorbidities | 98 |
hemolytic | 98 |
preventing | 98 |
suffering | 98 |
note | 98 |
autopsy | 98 |
reasons | 97 |
seropositive | 97 |
plt | 97 |
entire | 97 |
minor | 97 |
maintained | 97 |
nct | 97 |
humoral | 97 |
communication | 96 |
der | 96 |
enzyme | 96 |
media | 96 |
indicating | 96 |
warranted | 96 |
healthcare | 96 |
sequence | 96 |
innate | 96 |
worsening | 96 |
pbsct | 96 |
inpatient | 95 |
social | 95 |
cut | 95 |
typical | 95 |
september | 95 |
candidiasis | 95 |
sufficient | 95 |
goal | 95 |
abo | 94 |
costs | 94 |
progressed | 94 |
beyond | 94 |
dr | 94 |
summary | 94 |
stay | 94 |
variety | 94 |
differential | 94 |
ud | 94 |
domain | 94 |
fact | 94 |
gm | 94 |
march | 94 |
missense | 94 |
exon | 94 |
colony | 94 |
efficiency | 94 |
aplasia | 94 |
recovered | 93 |
karyotype | 93 |
registered | 93 |
screen | 93 |
alloreactive | 93 |
enhanced | 93 |
hand | 93 |
define | 93 |
achieving | 93 |
recombinant | 93 |
obstruction | 92 |
extracorporeal | 92 |
creatinine | 92 |
atopic | 92 |
crucial | 92 |
monthly | 92 |
subgroup | 92 |
antithymocyte | 92 |
mesenchymal | 92 |
genomic | 92 |
sc | 92 |
heterogeneous | 92 |
transduced | 92 |
subgroups | 92 |
completely | 92 |
iu | 92 |
donation | 92 |
close | 92 |
medium | 92 |
extended | 92 |
success | 92 |
chimeric | 91 |
positivity | 91 |
throughout | 91 |
eleven | 91 |
august | 91 |
interactions | 91 |
survived | 91 |
appeared | 91 |
allowed | 91 |
cik | 91 |
fluconazole | 91 |
acceptable | 91 |
april | 91 |
uk | 91 |
inferior | 91 |
cov | 91 |
urd | 90 |
make | 90 |
enteropathy | 90 |
planned | 90 |
substantial | 90 |
yr | 90 |
pbmcs | 90 |
amount | 90 |
targets | 90 |
vomiting | 90 |
decline | 90 |
septic | 89 |
ir | 89 |
extremely | 89 |
relapses | 89 |
shorter | 89 |
naive | 89 |
evaluating | 89 |
eculizumab | 89 |
profound | 89 |
sequential | 89 |
vector | 89 |
treating | 89 |
gata | 89 |
managed | 88 |
limitations | 88 |
detailed | 88 |
consider | 88 |
demonstrates | 88 |
fev | 88 |
demographic | 88 |
systems | 88 |
mechanical | 87 |
incidences | 87 |
diversity | 87 |
responsible | 87 |
mature | 87 |
measure | 87 |
forty | 87 |
spontaneous | 87 |
allergic | 87 |
epidemiology | 87 |
content | 87 |
catheter | 87 |
nature | 87 |
concomitant | 87 |
ages | 87 |
cross | 87 |
areas | 87 |
modality | 87 |
hazard | 87 |
hscs | 86 |
regular | 86 |
requires | 86 |
lohc | 86 |
fa | 86 |
suitable | 86 |
nearly | 86 |
nbs | 86 |
rarely | 86 |
thrombotic | 86 |
asthma | 86 |
hdt | 86 |
bronchiectasis | 86 |
opportunistic | 86 |
patterns | 86 |
attributed | 86 |
abl | 86 |
autoantibodies | 86 |
metapneumovirus | 86 |
depression | 86 |
pneumoniae | 86 |
systematic | 85 |
cant | 85 |
image | 85 |
epstein | 85 |
murine | 85 |
infiltration | 85 |
letermovir | 85 |
efficient | 85 |
designed | 85 |
questionnaire | 85 |
ligand | 85 |
otherwise | 85 |
nervous | 85 |
concerning | 85 |
predictors | 85 |
global | 85 |
matching | 85 |
immediately | 84 |
stopped | 84 |
mucosa | 84 |
recognition | 84 |
enriched | 84 |
exhibited | 84 |
pro | 84 |
pnh | 84 |
shock | 84 |
surviving | 84 |
biomarkers | 84 |
maturation | 84 |
pneumocystis | 84 |
proposed | 84 |
techniques | 84 |
necrosis | 84 |
pairs | 84 |
slightly | 83 |
admissions | 83 |
arthritis | 83 |
ngs | 83 |
device | 83 |
changed | 83 |
probable | 83 |
tetanus | 83 |
itd | 83 |
continue | 83 |
conclude | 83 |
stimulating | 83 |
mhc | 83 |
see | 83 |
intracellular | 83 |
physician | 83 |
pathways | 83 |
avoid | 83 |
cervical | 83 |
completion | 83 |
phenotypic | 83 |
reach | 83 |
overload | 83 |
cancers | 83 |
diabetes | 83 |
minimum | 82 |
mycobacterial | 82 |
encephalitis | 82 |
regulation | 82 |
dental | 82 |
living | 82 |
dermatitis | 82 |
nr | 82 |
node | 82 |
cerebral | 82 |
gof | 82 |
comprehensive | 82 |
restricted | 82 |
exact | 82 |
lacking | 82 |
era | 82 |
probably | 82 |
whose | 82 |
tlr | 82 |
definitive | 82 |
employed | 82 |
elisa | 81 |
respect | 81 |
contact | 81 |
reason | 81 |
infl | 81 |
vitamin | 81 |
workup | 81 |
thymocyte | 81 |
properties | 81 |
ikbkb | 81 |
neurologic | 81 |
experimental | 81 |
technology | 81 |
barr | 81 |
standardized | 81 |
photopheresis | 81 |
preparative | 81 |
spleen | 81 |
replete | 81 |
cultured | 81 |
increasingly | 81 |
focus | 80 |
sp | 80 |
osteosarcoma | 80 |
nasal | 80 |
scans | 80 |
nodes | 80 |
always | 80 |
submitted | 80 |
appear | 80 |
fatigue | 80 |
clonal | 80 |
hundred | 80 |
histological | 80 |
routinely | 80 |
tnc | 80 |
igrt | 79 |
alc | 79 |
suspicion | 79 |
cvc | 79 |
functioning | 79 |
varicella | 79 |
grades | 79 |
account | 79 |
fraction | 79 |
phosphorylation | 79 |
regions | 79 |
mmud | 79 |
prompt | 79 |
hypothesized | 78 |
xiap | 78 |
born | 78 |
pos | 78 |
empiric | 78 |
existing | 78 |
amphotericin | 78 |
rt | 78 |
practices | 78 |
problem | 78 |
alterations | 78 |
gcsf | 78 |
pressure | 78 |
maternal | 78 |
hemolysis | 78 |
usa | 78 |
clinicians | 78 |
sle | 78 |
beginning | 78 |
gr | 78 |
lavage | 78 |
ist | 78 |
ls | 78 |
measurements | 77 |
vaccinated | 77 |
pcp | 77 |
specificity | 77 |
bcr | 77 |
ia | 77 |
primarily | 77 |
dpb | 77 |
vgpr | 77 |
mutated | 77 |
cid | 77 |
subtypes | 77 |
persistence | 77 |
validation | 77 |
periods | 77 |
organisms | 77 |
notable | 77 |
fifty | 76 |
threshold | 76 |
seem | 76 |
perform | 76 |
consideration | 76 |
hdc | 76 |
identifying | 76 |
hu | 76 |
composition | 76 |
transduction | 76 |
germany | 76 |
pk | 76 |
injection | 76 |
selective | 76 |
immediate | 76 |
parental | 76 |
sixty | 76 |
blast | 76 |
immunomodulatory | 76 |
twelve | 75 |
technique | 75 |
europe | 75 |
bv | 75 |
suggestive | 75 |
untreated | 75 |
produce | 75 |
implementation | 75 |
pancytopenia | 75 |
classical | 75 |
encoding | 75 |
polymerase | 75 |
establish | 75 |
immunization | 75 |
follows | 74 |
haploinsufficiency | 74 |
corresponding | 74 |
decreasing | 74 |
screened | 74 |
pidd | 74 |
tuberculosis | 74 |
markedly | 74 |
food | 74 |
compound | 74 |
providing | 74 |
independently | 74 |
confidence | 74 |
copy | 74 |
repair | 74 |
find | 74 |
defective | 74 |
electronic | 73 |
encouraging | 73 |
methylprednisolone | 73 |
platform | 73 |
settings | 73 |
thought | 73 |
highlights | 73 |
lasting | 73 |
characterize | 73 |
alloreactivity | 73 |
toxic | 73 |
certain | 73 |
clones | 73 |
concurrent | 73 |
eczema | 73 |
guide | 73 |
poorly | 73 |
live | 73 |
functions | 73 |
gf | 73 |
biological | 73 |
software | 73 |
relapsing | 73 |
bcl | 72 |
joint | 72 |
possibility | 72 |
delivery | 72 |
genetically | 72 |
ctl | 72 |
importantly | 72 |
schedule | 72 |
hospitalizations | 72 |
campath | 72 |
cc | 72 |
ma | 72 |
father | 72 |
mc | 72 |
challenges | 72 |
generalized | 72 |
much | 72 |
fevers | 72 |
xla | 72 |
rabbit | 72 |
responding | 72 |
notably | 72 |
meeting | 72 |
itp | 72 |
implemented | 72 |
cantly | 71 |
kinetics | 71 |
cytopenia | 71 |
otitis | 71 |
limit | 71 |
pilot | 71 |
fresh | 71 |
etanercept | 71 |
world | 71 |
produced | 71 |
component | 71 |
predictor | 71 |
japan | 71 |
exposed | 71 |
influenced | 71 |
obtain | 71 |
albumin | 71 |
coronavirus | 71 |
abscesses | 71 |
bilirubin | 71 |
nod | 71 |
aerosolized | 71 |
utilization | 71 |
splenectomy | 71 |
light | 71 |
wes | 71 |
reactivations | 71 |
nevertheless | 71 |
ultimately | 71 |
processed | 71 |
introduced | 71 |
crp | 70 |
varied | 70 |
affects | 70 |
variability | 70 |
undetectable | 70 |
barriers | 70 |
sister | 70 |
protection | 70 |
vzv | 70 |
competing | 70 |
ag | 70 |
dendritic | 70 |
challenge | 70 |
lungs | 70 |
aki | 70 |
categories | 70 |
transferred | 70 |
harvest | 70 |
acyclovir | 70 |
utilized | 70 |
ro | 70 |
subject | 70 |
enhance | 70 |
committee | 70 |
ranges | 70 |
step | 70 |
stool | 69 |
rest | 69 |
stages | 69 |
thrive | 69 |
stress | 69 |
tac | 69 |
curve | 69 |
carcinoma | 69 |
typing | 69 |
ch | 69 |
algorithm | 69 |
hscts | 69 |
muscle | 69 |
clinimacs | 69 |
sought | 69 |
interaction | 69 |
measurement | 69 |
ldh | 69 |
specimens | 69 |
improvements | 68 |
lrtd | 68 |
transfused | 68 |
placed | 68 |
exam | 68 |
nucleated | 68 |
challenging | 68 |
latter | 68 |
und | 68 |
lymphoproliferation | 68 |
pc | 68 |
great | 68 |
ic | 68 |
subpopulations | 68 |
stromal | 67 |
fc | 67 |
bl | 67 |
terminal | 67 |
taking | 67 |
advantage | 67 |
possibly | 67 |
tolerability | 67 |
persisted | 67 |
molecules | 67 |
epithelial | 67 |
benefits | 67 |
cp | 67 |
kit | 67 |
rs | 67 |
somatic | 67 |
membrane | 66 |
nonmalignant | 66 |
endpoints | 66 |
journal | 66 |
reduces | 66 |
tapered | 66 |
cir | 66 |
treo | 66 |
herpesvirus | 66 |
transition | 66 |
dosage | 66 |
closely | 66 |
lad | 66 |
bsi | 66 |
lost | 65 |
tx | 65 |
apds | 65 |
altered | 65 |
processing | 65 |
logistic | 65 |
abscess | 65 |
migration | 65 |
special | 65 |
plan | 65 |
resection | 65 |
organizing | 65 |
multivariable | 65 |
staphylococcus | 65 |
edema | 65 |
reporting | 65 |
sent | 65 |
ns | 65 |
thrombosis | 65 |
sessions | 65 |
generate | 65 |
alt | 65 |
breast | 65 |
regardless | 65 |
components | 65 |
proved | 65 |
hemophagocytic | 65 |
western | 64 |
institutions | 64 |
pha | 64 |
bronchoalveolar | 64 |
italy | 64 |
mismatches | 64 |
trough | 64 |
label | 64 |
emptive | 64 |
means | 64 |
mf | 64 |
mental | 64 |
profiles | 64 |
modalities | 64 |
posaconazole | 64 |
frequencies | 63 |
pgf | 63 |
microangiopathy | 63 |
unusual | 63 |
largest | 63 |
pediatrics | 63 |
inkt | 63 |
mutant | 63 |
cardiovascular | 63 |
original | 63 |
intermittent | 63 |
lymphohistiocytosis | 63 |
network | 63 |
financial | 63 |
issues | 63 |
aims | 63 |
recommend | 63 |
sclerosis | 63 |
md | 63 |
zoster | 63 |
plays | 63 |
separate | 63 |
leukapheresis | 63 |
quantification | 63 |
serve | 63 |
presentations | 63 |
bloodstream | 62 |
till | 62 |
pp | 62 |
rescue | 62 |
unfortunately | 62 |
attention | 62 |
offers | 62 |
measles | 62 |
men | 62 |
cdc | 62 |
sds | 62 |
igd | 62 |
ascites | 62 |
eosinophilia | 62 |
tumour | 62 |
spp | 62 |
neg | 62 |
questions | 62 |
emerging | 62 |
amino | 62 |
upfront | 62 |
appearance | 62 |
genome | 61 |
mcg | 61 |
eventually | 61 |
summarized | 61 |
explored | 61 |
funding | 61 |
estimate | 61 |
guideline | 61 |
minutes | 61 |
never | 61 |
decades | 61 |
im | 61 |
soluble | 61 |
von | 61 |
tam | 61 |
ncf | 61 |
leukocytes | 61 |
classic | 61 |
peg | 61 |
intervals | 61 |
extracted | 61 |
field | 61 |
mp | 61 |
correlate | 61 |
interleukin | 61 |
parent | 61 |
developmental | 61 |
comorbidity | 61 |
dcs | 60 |
durable | 60 |
ikaros | 60 |
explore | 60 |
serotherapy | 60 |
vrti | 60 |
busulphan | 60 |
uid | 60 |
stroke | 60 |
processes | 60 |
man | 60 |
characteristic | 60 |
scig | 60 |
sinusoidal | 60 |
topical | 60 |
neck | 60 |
allowing | 60 |
accompanied | 60 |
counseling | 60 |
ulcers | 60 |
inhibitory | 60 |
lab | 60 |
urinary | 60 |
comprised | 60 |
humans | 60 |
aes | 60 |
address | 60 |
assessments | 60 |
continues | 60 |
heparin | 60 |
airway | 60 |
qpcr | 59 |
controversial | 59 |
concerns | 59 |
examine | 59 |
equal | 59 |
advances | 59 |
mitogen | 59 |
thyroid | 59 |
sinopulmonary | 59 |
historical | 59 |
mouth | 59 |
largely | 59 |
offered | 59 |
cs | 59 |
thawing | 59 |
vte | 59 |
thereafter | 59 |
soft | 59 |
facs | 59 |
nutrition | 59 |
country | 59 |
scoring | 59 |
equivalent | 59 |
killing | 59 |
characterization | 59 |
fertility | 59 |
meningitis | 59 |
tomography | 59 |
infiltrates | 59 |
focal | 59 |
limiting | 59 |
defi | 59 |
intravenously | 59 |
nutritional | 58 |
promote | 58 |
bcv | 58 |
filgrastim | 58 |
chemo | 58 |
regard | 58 |
room | 58 |
aic | 58 |
nonmyeloablative | 58 |
act | 58 |
familial | 58 |
hypothesis | 58 |
investigations | 58 |
adaptive | 58 |
annual | 58 |
biomarker | 58 |
evolution | 58 |
compartment | 58 |
percentile | 58 |
incompatibility | 58 |
ca | 58 |
ultrasound | 58 |
palivizumab | 58 |
microbiota | 58 |
ray | 58 |
doi | 58 |
improves | 58 |
cfu | 58 |
pathological | 58 |
partially | 58 |
blinatumomab | 58 |
voc | 58 |
strains | 58 |
domains | 58 |
gd | 58 |
observational | 57 |
relation | 57 |
reactivity | 57 |
bw | 57 |
infancy | 57 |
ild | 57 |
understood | 57 |
longitudinal | 57 |
crisis | 57 |
way | 57 |
thereby | 57 |
nodules | 57 |
lentiviral | 57 |
grading | 57 |
insufficient | 57 |
serology | 57 |
uncommon | 57 |
displayed | 57 |
computed | 57 |
sixteen | 57 |
utilizing | 57 |
arms | 57 |
candidate | 56 |
insufficiency | 56 |
compatible | 56 |
alleles | 56 |
rvi | 56 |
wild | 56 |
maintain | 56 |
carrying | 56 |
valganciclovir | 56 |
presents | 56 |
proliferative | 56 |
ones | 56 |
referral | 56 |
granulocytes | 56 |
progenitors | 56 |
pathologic | 56 |
mobilisation | 56 |
experiments | 56 |
february | 56 |
multiorgan | 56 |
sub | 56 |
trecs | 56 |
macrophages | 56 |
pres | 56 |
predicting | 56 |
boys | 56 |
coagulation | 56 |
diverse | 56 |
usage | 56 |
linear | 56 |
definition | 56 |
discharged | 56 |
discussed | 56 |
lineage | 56 |
normalized | 56 |
temperature | 55 |
focused | 55 |
enrollment | 55 |
cxcl | 55 |
osteomyelitis | 55 |
lv | 55 |
solution | 55 |
localized | 55 |
board | 55 |
near | 55 |
offer | 55 |
carrier | 55 |
service | 55 |
lenalidomide | 55 |
sinusitis | 55 |
colon | 55 |
driven | 55 |
fresenius | 55 |
demonstrating | 55 |
example | 55 |
withdrawal | 55 |
fifteen | 55 |
express | 55 |
facilitate | 55 |
back | 55 |
tocilizumab | 55 |
ataxia | 55 |
irradiated | 55 |
ligands | 55 |
substitution | 55 |
tb | 55 |
decade | 54 |
brother | 54 |
sha | 54 |
metabolism | 54 |
metastasis | 54 |
ipex | 54 |
title | 54 |
doc | 54 |
north | 54 |
timely | 54 |
tm | 54 |
instead | 54 |
producing | 54 |
thymus | 54 |
irb | 54 |
true | 54 |
dasatinib | 54 |
prominent | 54 |
fungi | 54 |
histology | 54 |
pubertal | 54 |
premature | 54 |
streptococcus | 54 |